NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Assertio Holdings, Inc. (ASRT) Stock Analysis

Assertio Holdings, Inc. (ASRT) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

ASRT

$23.50

$0.00 (0.00%)

Last trade June 29, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ASRT with… →

ASRT Key Statistics

As of Jun 29, 2026
Trading
Open
$23.50
Previous Close
$23.50
52-Week Range
8.61–23.46
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.45
Valuation
Market Cap
$151.60M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
9.09
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.48
EPS (ttm)Profit attributable to each share over the last twelve months.
−5.55
Financials (FY)
Profit marginThe share of revenue left as profit after all costs and taxes.
−34.94%
1-Year Return
+3515.38%
Dividend and dates
Avg Volume
294.88K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ASRT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+159.10%
2025+942.53%
2024 (partial year)+3.57%

As of June 29, 2026.

ASRT Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricASRTDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio1.482.3035% below
Profit margin−34.94%−3.14%31.8 pts below

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Assertio Holdings, Inc. (ASRT) is capitalised at $151.60M on the latest close. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. Headcount on file is 53.

The most recent close on file for ASRT is $23.50, dated June 29, 2026. The close was unchanged from the previous session. The 52-week range on file runs from $8.61 to $23.46. The latest close sits 172.94% above that 52-week low.

Financial Health

Trailing twelve-month revenue on file is $102.16M. The reported profit margin is −34.94%. That is 31.8 percentage points below the Drug Manufacturers - Specialty & Generic median of −3.14%. Trailing earnings per share are −5.55.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The forward P/E on file is 9.09. Measured against sales, the shares trade at 1.48 times revenue. On price-to-sales that is 35.37% below the Drug Manufacturers - Specialty & Generic median of 2.3. 103 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

The reported beta is 0.45. Daily returns over the trailing 1 year annualize to a volatility of 1,469.24%. Over the trailing twelve months the price has returned +3,515.38%. The stored price history starts on December 19, 2024, and the total return since then is +2,697.62%.

Growth & Income

No dividend is on file for ASRT.

The record holds one complete calendar year, 2025, which returned +942.53%. 2026 is still running; the price is +159.10% year to date.

Peer Comparison

Assertio Holdings, Inc. (ASRT) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Assertio Holdings, Inc. ASRT $151.60M —
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Assertio Holdings, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of June 29, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Assertio Holdings, Inc.

Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Visit website →